Akèy › Kansè pwostat › Virginia › Arlington
Etid klinik pou Kansè pwostat nan Arlington, VA
17 etid pou Kansè pwostat ap chèche patisipan nan sit nan ak bò kote Arlington (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Ap rekriteFaz 3
- Inova Schar Cancer Institute ( Site 0017), Fairfax · 11 mi lwen
- Virginia Cancer Specialists (VCS) ( Site 8004), Fairfax · 11 mi lwen
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Ap rekriteFaz 2/3
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Ap rekriteFaz 1
- Investigational Site number: 404, Fairfax · 11 mi lwen
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- NEXT Oncology, Fairfax · 11 mi lwen
The Vanguard Study: Testing a New Way to Screen for Cancer
Ap rekriteVolontè an sante akeyi
- Inova Schar Cancer Institute, Fairfax · 11 mi lwen
- Inova Fair Oaks Hospital, Fairfax · 11 mi lwen
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
Ap rekriteFaz 2
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Ap rekriteFaz 1
- Virginia Cancer Specialists PC, Fairfax · 11 mi lwen
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
Ap rekriteFaz 1/2
- NEXT Oncology - Virginia, Fairfax · 11 mi lwen
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Ap rekriteFaz 1
- Virginia Oncology Associates, Fairfax · 11 mi lwen
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
Ap rekrite
- Inova Schar Cancer Institute, Fairfax · 11 mi lwen
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
Ap rekriteFaz 1/2
- NEXT Oncology, Fairfax · 11 mi lwen
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- NEXT Oncology Virginia, Fairfax · 11 mi lwen
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Ap rekriteFaz 1/2
- NEXT, Virginia, Fairfax · 11 mi lwen
Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture
Ap rekrite
- Inova Schar Cancer Institute, Fairfax · 11 mi lwen
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Research Site 102, Fairfax · 11 mi lwen
- Research Site 112, Fairfax · 11 mi lwen
Etid Kansè pwostat nan lòt vil
- New York City, NY103 etid
- Houston, TX76 etid
- Los Angeles, CA61 etid
- Boston, MA59 etid
- St. Louis, MO46 etid
- Chicago, IL45 etid
- San Francisco, CA45 etid
- Philadelphia, PA44 etid
- Baltimore, MD43 etid
- Nashville, TN42 etid
- Seattle, WA42 etid
- Washington, DC38 etid
Lòt etid nan Arlington
- Kansè Poumon ki pa ti selil104 etid
- Kansè Metastatik53 etid
- Kansè kolorektal52 etid
- Kansè (tout kalite)48 etid
- Kansè nan tete46 etid
- Kansè ovè46 etid
- Kansè poumon41 etid
- Kansè Endomèt39 etid
- Kansè pankreyas33 etid
- Karsinòm selil skuamèz tèt ak kou26 etid
- Kansè poumon selil ti23 etid
- Kansè tete negatif triple20 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.